Supernus and Indivior's All-Stock Merger Isn't a Normal Arbitrage Trade

Merger news usually comes in one of two flavors: a company pays cash for another company, or two companies swap stock and call it even. Supernus Pharmaceuticals and Indivior Pharmaceuticals just did the second one, and the mechanics are different enough from the usual "merger arbitrage" story that they're worth walking through on their own.

What was announced

On August 3, 2026, Supernus (Nasdaq: SUPN) and Indivior (Nasdaq: INDV) — both companies focused on central nervous system (CNS) drugs — announced a definitive agreement to combine in an all-stock merger of equals. Under the deal, each share of Supernus converts into 1.5401 shares of Indivior common stock, a fixed ratio that won't adjust if either stock moves before the deal closes. When the dust settles, Indivior shareholders are expected to own about 56.5% of the combined company and Supernus shareholders about 43.5%, on a fully diluted basis.

The combined company will be named Supernus, Inc., trade under the ticker SUPN, and be headquartered in Rockville, Maryland — Supernus's current home base — with Supernus's current CEO, Jack Khattar, running the combined business. Indivior shareholders are also set to receive a one-time $1.0 billion special cash dividend right before the deal closes, funded by a mix of a new term loan and existing cash. The companies expect roughly $2.2 billion in pro forma annual revenue and about $125 million in annual cost savings once combined, with a close targeted for the fourth quarter of 2026, pending shareholder votes at both companies and regulatory sign-off.

Both stocks moved on the news, though by how much depends on which moment you look at: Supernus jumped as much as 20%-plus in premarket trading and as much as 16% intraday, but closed the day up a more modest roughly 3% — a gap that suggests the market's initial excitement cooled somewhat once traders had time to think through the deal terms. Indivior's reaction was messier: shares popped nearly 10% in premarket trading on the combined merger-and-special-dividend news, but multiple outlets reported the stock giving back much of that move during the regular session and finishing the day lower rather than higher — a reminder that a premarket pop and where a stock actually settles by the close can tell two different stories on merger news.

Why this isn't the arbitrage trade you might expect

If you've read about merger arbitrage before, the usual setup is: Company A agrees to buy Company B for a fixed cash price — say $50 a share — and Company B's stock trades a little below $50 until the deal actually closes, with that gap (the "spread") reflecting the market's assessment of deal-completion risk. Traders try to capture that spread.

None of that applies cleanly here, because there's no cash offer price to measure a spread against. Supernus shareholders aren't getting paid $X per share — they're getting 1.5401 shares of Indivior stock, and Indivior shareholders keep their existing shares, which now represent ownership of a different, larger company. The "value" of the deal to either side depends entirely on what the combined company's stock is actually worth once it's trading as one entity — which is unknowable in advance, unlike a cash number.

That structural difference introduces three risks that a cash-deal arbitrage trade doesn't have in the same form:

• Exchange-ratio risk. The 1.5401 ratio is fixed and won't move to compensate if one company's business does better or worse than the other's between now and closing — if Supernus outperforms Indivior over that stretch, for instance, Supernus shareholders still don't get more shares to reflect it; the ratio is locked in.
• Deal-completion risk, in both directions. A cash deal mostly has one company's shareholders voting on whether to accept a price. Here, both companies' shareholders have to approve the deal, and a failed vote at either company, or a blocked regulatory review, could unwind it — meaning there are more points where the deal could fall apart than in a typical one-sided acquisition.
• Dilution. Supernus shareholders currently own 100% of Supernus. After the deal, they'll own roughly 43.5% of a bigger combined company. That's not automatically bad — it depends on whether the combined company is worth more per share than standalone Supernus would have been — but it's a real structural change in what each share represents, not just a price change.

How this changes the options conversation

Because there's no cash "deal price" to measure against, the options strategies people typically associate with merger arbitrage on a cash deal — buying puts on the target near the offer price to hedge deal-break risk, for instance — don't map onto this situation the same way. Anyone thinking through options exposure to a stock-for-stock deal like this one is really thinking about a relative-value or pairs-style question between the two stocks (how SUPN and INDV move relative to each other, since the exchange ratio ties their eventual value together) rather than a single stock's distance from a fixed cash target. That's a mechanically different, generally more complex trade to construct and size than a standard cash-deal arbitrage position, and it carries its own basis risk if the two stocks' options don't move in the expected relationship.

None of this is a suggestion to put on any specific position in either stock. The point is narrower: "merger arbitrage" is not one uniform strategy, and the cash-deal version most retail materials describe simply doesn't apply to a stock-for-stock merger of equals like this one.

The bottom line

A merger of equals like Supernus-Indivior swaps a simple cash-offer question ("will this deal close at this price?") for a more layered one involving relative value, dilution, and a locked-in exchange ratio that can't adjust for either company's performance between now and closing. Some deal terms — including the exact regulatory approvals required and the specific fourth-quarter closing date — haven't been spelled out yet and are still pending in the companies' own disclosures. Anyone evaluating a position in either stock around this deal should treat it as a distinct risk profile from a cash-buyout arbitrage situation, and work through the specifics with a financial professional rather than applying a generic merger-arb template.

This article is educational commentary on public market events, not personalized investment, trading, or tax advice.